Drugs / LCAR-M23
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04562298 | Oct 2020 → Jun 2022 | malignant epithelial tumor of ovary | Shanghai East Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-M23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04562298 ↗ |
| Modality | Cell therapy | “a CAR-T Cell Therapy” NCT04562298 ↗ |
| Target | MSLN | “Targeting MSLN” NCT04562298 ↗ |